• BioVie highlighted bezisterim, an oral, blood-brain barrier-penetrating small molecule targeting TNFα-driven inflammation across Parkinson’s, Long COVID, Alzheimer’s.
• Topline data expected in 3Q 2026 for SUNRISE-PD Phase 2b in Parkinson’s disease, with Long COVID Phase 2 results also slated for 3Q 2026.
• Parkinson’s readouts emphasized EPNIC-15, a composite spanning MDS-UPDRS Parts I-III and PDSS-2 to capture motor and non-motor change.
• BIV201, a continuous IV terlipressin formulation for ascites, positioned as Phase 3-ready with an FDA-agreed single registrational trial design.
• Pipeline materials cited annual US sales potential estimates of $3 billion for Parkinson’s, $10 billion for Long COVID, $30 billion for Alzheimer’s, $1.6 billion for ascites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.